Interleukin-1 Blockade in Recently Decompensated Heart Failure (RED-HART)

Virginia Commonwealth University (VCU)

Status and phase: Completed; Phase 3; Phase 2

Conditions: Heart Failure

Treatments: Drug: Anakinra (weeks 3-12); Drug: Placebo; Drug: Anakinra (weeks 1-2)

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT01936909

1R34HL117026 (U.S. NIH Grant/Contract)

RED-HART (HM15339)

Details and patient eligibility

About

The RED-HART is a randomized double-blinded placebo-controlled study of Anakinra (IL-1 blocker) in patients with recently decompensated heart failure to determine the safety and efficacy in terms of aerobic exercise capacity and ventilatory efficiency measured with a cardiopulmonary exercise test.

Enrollment: 60 patients

Sex: All

Ages: 21 to 130 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

All 6 criteria need to be met for enrollment of the patient in the study

1. Primary diagnosis for hospitalization is decompensated heart failure established as the finding at admission of all 2 conditions listed below:

   1. dyspnea or respiratory distress or tachypnea at rest or with minimal exertion;

   2. evidence of elevated cardiac filling pressure or pulmonary congestion (at least one of the conditions must be met);

      • pulmonary congestion/edema at physical exam OR chest X-Ray;
      • plasma Brain Natriuretic Peptide (BNP) levels ≥200 pg/ml;
      • invasive measurement of left ventricular end-diastolic pressure >18 mmHg or of pulmonary artery occluding pressure (wedge) >16 mmHg.

2. The patient has a prior documentation of impaired left ventricular systolic function (ejection fraction <50%) at most recent assessment by any imaging modality (within 12 months).

3. The patient is now clinically stable and meets standard criteria for hospital discharge as documented by all the 3 conditions listed below:

   1. absence of dyspnea or pulmonary congestion/distress at rest;
   2. absence of pitting edema in the lower extremities, or in any other region;
   3. stable hemodynamic parameters (blood pressure, heart rate).

4. The patient is of age ≥21 years old, and is willing and able to provide written informed consent.

5. The patient is willing and able to comply with the protocol (i.e. self administration of the treatment, and exercise protocol).

6. The patient has screening plasma C-reactive protein levels >2 mg/L.

Exclusion Criteria Subjects will not be eligible if they meet any of the following 15 exclusion criteria.

1. The primary diagnosis for admission is NOT decompensated heart failure, including diagnosis of acute coronary syndromes, hypertensive urgency/emergency, tachy- or brady-arrhythmias.
2. Concomitant clinically significant comorbidities that would interfere with the execution or interpretation of the study including but not limited to acute coronary syndromes, uncontrolled hypertension or orthostatic hypotension, tachy- or brady-arrhythmias, acute or chronic pulmonary disease or neuromuscular disorders affecting respiration.
3. Recent (previous 3 months) or planned cardiac resynchronization therapy (CRT), coronary artery revascularization procedures, or heart valve surgeries.
4. Previous or planned implantation of left ventricular assist devices or heart-transplant.
5. Chronic use of intravenous inotropes.
6. Recent (<14 days) use of immunosuppressive or anti-inflammatory drugs (not including Non-Steroidal Anti-Inflammatory Drugs [NSAIDs]).
7. Chronic inflammatory disorder (including but not limited to rheumatoid arthritis, systemic lupus erythematosus).
8. Active infection (of any type);
9. Chronic/recurrent infectious disease (including Hepatitis B virus [HBV], Hepatitis C virus [HCV], and HIV/AIDS).
10. Prior (within the past 10 years) or current malignancy.
11. Any comorbidity limiting survival or ability to complete the study.
12. End stage kidney disease requiring renal replacement therapy.
13. Neutropenia (<2,000/mm3) or Thrombocytopenia (<50,000/mm3).
14. Pregnancy.
15. Angina, arrhythmias, or electrocardiograph (ECG) changes that limit maximum exertion during cardiopulmonary exercise testing obtained during the baseline testing.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

60 participants in 3 patient groups, including a placebo group

Anakinra (short)

Experimental group

Description:

Anakinra 100 mg daily for 2 weeks, followed by placebo for 10 weeks

Treatment:

Drug: Anakinra (weeks 1-2)

Anakinra (long)

Experimental group

Description:

Anakinra 100 mg daily for 12 weeks

Treatment:

Drug: Anakinra (weeks 1-2)

Drug: Anakinra (weeks 3-12)

Placebo

Placebo Comparator group

Description:

Placebo injections daily for 12 weeks

Treatment:

Drug: Placebo